X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WOCKHARDT LTD. AJANTA PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 20.9 16.7 125.5% View Chart
P/BV x 9.1 1.7 532.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AJANTA PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
WOCKHARDT LTD.
Mar-16
AJANTA PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,7202,000 86.0%   
Low Rs1,103706 156.3%   
Sales per share (Unadj.) Rs194.6403.7 48.2%  
Earnings per share (Unadj.) Rs45.229.5 153.4%  
Cash flow per share (Unadj.) Rs50.342.4 118.7%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0323.4 40.8%  
Shares outstanding (eoy) m88.77110.51 80.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.4 216.4%   
Avg P/E ratio x31.245.9 68.0%  
P/CF ratio (eoy) x28.131.9 87.9%  
Price / Book Value ratio x10.74.2 255.5%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,299149,509 83.8%   
No. of employees `000NA7.4 0.0%   
Total wages/salary Rs m2,5709,443 27.2%   
Avg. sales/employee Rs ThNM6,048.6-  
Avg. wages/employee Rs ThNM1,280.2-  
Avg. net profit/employee Rs ThNM441.5-  
INCOME DATA
Net Sales Rs m17,27544,614 38.7%  
Other income Rs m166970 17.2%   
Total revenues Rs m17,44245,584 38.3%   
Gross profit Rs m5,8075,038 115.3%  
Depreciation Rs m4511,426 31.6%   
Interest Rs m491,012 4.8%   
Profit before tax Rs m5,4743,570 153.3%   
Minority Interest Rs m0-65 0.0%   
Prior Period Items Rs m06 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460255 573.0%   
Profit after tax Rs m4,0143,257 123.3%  
Gross profit margin %33.611.3 297.7%  
Effective tax rate %26.77.1 373.7%   
Net profit margin %23.27.3 318.3%  
BALANCE SHEET DATA
Current assets Rs m7,63939,906 19.1%   
Current liabilities Rs m2,71518,423 14.7%   
Net working cap to sales %28.548.2 59.2%  
Current ratio x2.82.2 129.9%  
Inventory Days Days4390 47.9%  
Debtors Days Days7998 80.1%  
Net fixed assets Rs m6,91435,832 19.3%   
Share capital Rs m177553 32.0%   
"Free" reserves Rs m11,44230,370 37.7%   
Net worth Rs m11,72135,739 32.8%   
Long term debt Rs m14916,542 0.9%   
Total assets Rs m14,81479,522 18.6%  
Interest coverage x112.94.5 2,494.6%   
Debt to equity ratio x00.5 2.7%  
Sales to assets ratio x1.20.6 207.9%   
Return on assets %27.45.4 510.9%  
Return on equity %34.29.1 375.8%  
Return on capital %46.58.7 537.8%  
Exports to sales %55.111.6 475.3%   
Imports to sales %6.04.5 134.6%   
Exports (fob) Rs m9,5275,177 184.0%   
Imports (cif) Rs m1,0381,990 52.1%   
Fx inflow Rs m10,4227,589 137.3%   
Fx outflow Rs m1,6782,878 58.3%   
Net fx Rs m8,7444,711 185.6%   
CASH FLOW
From Operations Rs m3,264716 455.8%  
From Investments Rs m-2,093-8,182 25.6%  
From Financial Activity Rs m-1,1862,543 -46.6%  
Net Cashflow Rs m-15-4,923 0.3%  

Share Holding

Indian Promoters % 73.8 74.5 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.3 67.4%  
FIIs % 7.6 7.7 98.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 67,757 30.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - J.B.CHEMICALS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS